NASDAQ:OCS Oculis Q1 2026 Earnings Report $9.27 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$9.28 +0.02 (+0.16%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oculis EPS ResultsActual EPS-$0.63Consensus EPS -$0.49Beat/MissMissed by -$0.14One Year Ago EPSN/AOculis Revenue ResultsActual Revenue$0.26 millionExpected Revenue$0.25 millionBeat/MissBeat by +$8.00 thousandYoY Revenue GrowthN/AOculis Announcement DetailsQuarterQ1 2026Date5/8/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time1:00AM ETUpcoming EarningsOculis' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Oculis Earnings HeadlinesOculis (NASDAQ:OCS) Reaches New 1-Year Low - What's Next?September 26 at 5:41 AM | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 23, 2026 | americanbankingnews.comUnder $5, Is This Nasdaq Early to America's Next Defense Boom?Small drones costing hundreds of dollars can now rival tanks and equipment worth millions, a shift Ukraine has already proven in combat. The Pentagon wants around 300,000 drones, and Washington is pushing domestic manufacturing and secure supply chains. The global drone market is projected to reach 182.4 billion dollars by 2033. One Nasdaq company, with over 25 years developing professional drone technology, patents, and real-world tested systems, still trades under 5 dollars.September 28 at 1:00 AM | i2i Marketing Group, LLC (Ad)HC Wainwright Forecasts Strong Price Appreciation for Oculis (NASDAQ:OCS) StockSeptember 20, 2026 | americanbankingnews.comOculis Holding AG: Navigating Through Major Trial SetbackSeptember 17, 2026 | seekingalpha.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesSeptember 17, 2026 | globenewswire.comSee More Oculis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email. Email Address About OculisOculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures. Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery. The company is also developing other investigational candidates, including OCS-02, a topical anti-inflammatory therapy for conditions such as dry eye disease, and OCS-05, a potential neuroprotective treatment for disorders affecting the optic nerve and retina. Founded in Europe, Oculis is headquartered in Zug, Switzerland, and has developed an international operating presence that includes activities in Europe and the United States. The company’s programs are intended for global markets, subject to clinical development results and regulatory approval. Oculis is led by Chief Executive Officer Riad Sherif, M.D.View Oculis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
